【私募调研记录】名禹资产调研润都股份

Group 1 - The core viewpoint of the news is that Mingyu Asset Management has conducted research on a listed company, Rundu Co., focusing on the development and commercialization of a new drug, and the company's operational performance [1] - Rundu Co. is advancing the registration application for its innovative drug, a hydrochloride injection of dehydroevodiamine, which has shown good safety in Phase III clinical trials [1] - The company plans to promote the drug through its own marketing team and collaborative promotion, while exploring more innovative results in the field of synthetic biology [1] Group 2 - Rundu Co.'s production value has significantly increased, with improved synergy between its two major bases in Zhuhai and Jingmen, and a substantial rise in nicotine sales compared to the same period last year [1] - However, the increase in nicotine sales has not yet had a significant impact on the company's overall performance [1]